THToshihiko Hidaka

Toshihiko Hidaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Toshihiko Hidaka has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Perspectives of rheumatologists on the management of late-onset rheumatoid arthritis: a nationwide cross-sectional survey

    by Satoshi Takanashi, Yuko Kaneko, Yutaka Kawahito, Takashi Kida, Takahiko Sugihara, Toshihisa Kojima, Ryozo Harada, Michinori Ishitoku, Shintaro Hirata, Motomu Hashimoto, et al.

  • Human T-cell leukaemia virus type 1-associated myelopathy in patients with rheumatoid arthritis: A case series highlighting functional disability and diagnostic challenges

    by Masayuki Murai, Kunihiko Umekita, Risa Kudo, Masatoshi Kimura, Chihiro Iwao, Kosho Iwao, Takeshi Kawaguchi, Motohiro Matsuda, Shunichi Miyauchi, Yayoi Hashiba, et al.

    Objectives: Although rheumatoid arthritis (RA) and human T-cell leukaemia virus type 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) occasionally coexist, their clinical characteristics and patient outcomes remain poorly elucidated. Methods: We conducted a retrospective case series of five patients with RA complicated by HAM/TSP (HAM-RA) enrolled in the HTLV-1 Positive Rheumatoid Arthritis Miyazaki Registry. Clinical characteristics, functional status, quality of life, and HTLV-1–associated parameters were reviewed. Age- and sex-matched patients with HTLV-1–positive RA and HTLV-1–negative RA served as comparison groups. Results: All patients were women (median age, 67 years). HAM/TSP preceded RA onset in two patients, whereas RA developed first in three. Neurological disability substantially varies (Osame Motor Disability Scores of 2–11; three required wheelchair. Despite comparable RA disease activity, patients with HAM-RA demonstrated worse physical function and quality of life than controls. Patients with HAM-RA tended to have higher HTLV-1 proviral loads than HTLV-1–positive RA without HAM/TSP. Conclusions: HAM/TSP may develop before or after RA onset and cause substantial functional disability despite satisfactory control of arthritis. Screening for HTLV-1 may facilitate consideration of HAM/TSP and timely neurological evaluation. High proviral loads in patients with HAM-RA may warrant careful monitoring for the development of adult T-cell leukaemia/lymphoma.

  • Open Access

    Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis

    by Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, et al.

    Objectives: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset—late-onset RA (LORA) vs young-onset RA (YORA)—also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. Methods: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. Results: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. Conclusion: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.


  • Open Access

    Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis

    by Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, et al.

    Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited. Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort ( n = 252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3 ≥ third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI ≤ 10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world. Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent. Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.

  • Open Access

    HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional Observation Study

    by Kunihiko Umekita, Yuki Hashikura, Akira Takaki, Masatoshi Kimura, Katsumi Kawano, Chihiro Iwao, Shunichi Miyauchi, Takeshi Kawaguchi, Motohiro Matsuda, Yayoi Hashiba, et al.

    The study aims to assess the usefulness of human T-cell leukemia virus type 1 (HTLV-1)-infected cell analysis using flow cytometry (HAS-Flow) as a monitoring method for adult T-cell leukemia (ATL) development in HTLV-1-positive patients with rheumatoid arthritis (RA) under treatment with antirheumatic therapies. A total of 13 HTLV-1-negative and 57 HTLV-1-positive RA patients participated in this study, which was used to collect clinical and laboratory data, including HAS-Flow and HTLV-1 proviral load (PVL), which were then compared between the two groups. CADM1 expression on CD4+ cells in peripheral blood (PB) was used to identify HTLV-1-infected cells. The population of CADM1+ CD4+ cells was significantly higher in HTLV-1-positive RA patients compared to HTLV-1-negative RA patients. The population of CADM1+ CD4+ cells was correlated with HTLV-1 PVL values. There were no antirheumatic therapies affecting both the expression of CADM1 on CD4+ cells and PVLs. Six HTLV-1-positive RA patients who indicated both high HTLV-1 PVL and a predominant pattern of CADM1+ CD7neg CD4+ cells in HAS-Flow can be classified as high-risk for ATL progression. HAS-Flow could be a useful method for monitoring high-risk HTLV-1-positive RA patients who are at risk of developing ATL during antirheumatic therapies.


  • Open Access

    Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: A multicentre retrospective cohort study

    by Shunsuke Mori, Yukitaka Ueki, Tomoya Miyamura, Koji Ishii, Toshihiko Hidaka, Tamami Yoshitama, Kazuyoshi Nakamura, Yasuo Suenaga

    The aim is to evaluate outcomes and risk factors for death in patients with rheumatoid arthritis (RA) who developed Pneumocystis pneumonia (PCP). We included RA patients who were diagnosed with PCP at seven participating community hospitals between July 2005 and October 2020. Clinical features were compared between survivors and non-survivors. Disease-modifying antirheumatic drugs (DMARDs) before PCP onset and after PCP recovery were also examined. Seventy RA patients developed PCP, and among them, 60 (85.7%) received methotrexate (MTX) monotherapy (40%) or MTX combination therapy with other DMARDs (45.7%). PCP was more likely to occur after 12 months of MTX monotherapy and within 3 months of MTX combination therapy. Thirteen patients (18.6%) died despite PCP treatment. Multivariable logistic regression analysis revealed that coexisting RA-associated interstitial lung disease (odds ratio, 6.18; 95% confidence interval, 1.17–32.63) and delayed PCP treatment with anti-Pneumocystis drugs (odds ratio, 15.29; 95% confidence interval, 1.50–156.15) are significant risk factors for PCP mortality in RA patients. Most survivors successfully resumed DMARD therapy without PCP prophylaxis; one recurrent PCP case was observed during follow-up (median, 4.1 years). To avoid a treatment delay, RA patients should be followed up for signs and symptoms of PCP development, especially those with RA-associated interstitial lung disease.


  • Leukocytapheresis in rheumatoid arthritis

    by Toshihiko Hidaka, Yayoi Hashiba, Kazuyoshi Kubo, Yasufumi Kai, Keiichi Maeda


  • Open Access

    Calcinosis Cutis and Intestinal Pseudoobstruction in a Patient with Adult Onset Still's Disease Associated with Recurrent Relapses of Disordered Coagulopathy.

    by Tadashi Shinohara, Toshihiko Hidaka, Yasunori Matsuki, Kimihiro Suzuki, Fumitaka Ohsuzu

    Adult onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown origin, characterized by a typical spiking fever, evanescent salmon-colored rash, polyarthralgia, and myalgia. Calcinosis cutis and gastrointestinal involvement have rarely been noted in AOSD. We herein describe a 54-year-old woman who demonstrated repeated disseminated intravascular coagulation (DIC), and adult respiratory distress syndrome (ARDS), associated with AOSD. The patient also revealed a remarkable degree of digital calcinosis cutis and intestinal pseudoobstruction. A connective tissue disease, such as systemic sclerosis, might have been the underlying factor in the latter two symptoms.